Teecee Hailey-Fulfer, APRN
Psychiatric/Mental Health · Casper, WYNPI 1093117210
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 32.5% of the total. 2025 is the largest year on record at $999, 5.0 times the $199 reported in 2021. Among psychiatric/mental health clinicians in WY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$455
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$438
- Teva Pharmaceuticals USA, Inc.$392
- Vanda Pharmaceuticals Inc.$296
- Neurocrine Biosciences, Inc.$274
- plus $672 from 12 others
What the payments were for
- Food & beverage$3,47993%
- Education$2667%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 76 | $1,219 |
| Otsuka America Pharmaceutical, Inc. | 23 | $455 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $438 |
| Teva Pharmaceuticals USA, Inc. | 20 | $392 |
| Vanda Pharmaceuticals Inc. | 19 | $296 |
| Neurocrine Biosciences, Inc. | 10 | $274 |
| Sunovion Pharmaceuticals Inc. | 18 | $131 |
| Alkermes, Inc. | 6 | $115 |
| Supernus Pharmaceuticals, Inc. | 5 | $110 |
| Lundbeck LLC | 4 | $73 |
| Corium, LLC | 5 | $53 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Eisai Inc. | 2 | $38 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Merck | 1 | $11 |
How this compares
$3,745 in reported general payments places this provider in the 90th percentile of 76 psychiatric/mental health providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $146,664 |
| RexultiBrexpiprazole | 26 | $44,126 |
| VraylarCariprazine Hcl | 29 | $39,387 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,498 |
| DayvigoLemborexant | 26 | $8,532 |
| BelsomraSuvorexant | 18 | $8,235 |
| TrintellixVortioxetine Hydrobromide | 13 | $5,630 |
| PristiqDesvenlafaxine Succinate | 13 | $5,254 |
| Vilazodone Hcl | 13 | $1,734 |
| Oxcarbazepine | 18 | $1,338 |
| Duloxetine Hcl | 81 | $1,332 |
| Quetiapine Fumarate | 75 | $916 |
| Olanzapine | 64 | $839 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $821 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 39 | $751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $274 | $146,66418 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $455 | $44,12626 claims |
| AbbVieVraylar | $1,219 | $39,38729 claims |
| Alkermes, Inc.Lybalvi | $115 | $17,49811 claims |
| Eisai Inc.Dayvigo | $38 | $8,53226 claims |
| MerckBelsomra | $11 | $8,23518 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $23 | $5,63013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 76 psychiatric/mental health providers in Wyoming.
Other psychiatric/mental health in Casper
- Jennifer FraustoCasper$8K
- Michelle HipsakCasper$6K
- Rebekah LayherCasper$4K
- Jayme DonaldsonCasper$3K
- Karen GravesCasper$3K
- Sarah BurtCasper$3K
- Carla PootCasper$2K
- Crystal BardgettCasper$2K
- McKenzie FrederickCasper$1K
- Donna NurssCasper$975
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.